SCHEMBL25250171

SCHEMBL25250171

CC(C)(C)OC(=O)N(CCCCCC(=O)O)CCOCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.61
MAPT P10636 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
HDAC3 O15379 2/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC2 Q92769 2/20 0.43
NCOR2 Q9Y618 1/20 0.43
CTSB P07858 1/20 0.41
CCR6 P51684 1/20 0.41
PAX8 Q06710 1/20 0.41
ALOX5 P09917 1/20 0.41
PPARA Q07869 1/20 0.40
MAPK1 P28482 1/20 0.39
ADRA1A P35348 1/20 0.39
HDAC4 P56524 1/20 0.39
SLC6A3 Q01959 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24811995 0.95 L3MBTL1 (0.68) L3MBTL1MAPTRXFP1HDAC3HDAC1
SCHEMBL25801927 0.89 L3MBTL1 (0.63) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL21068526 0.85 L3MBTL1 (0.64) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL25801942 0.85 L3MBTL1 (0.56) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL4344803 0.84 L3MBTL1 (0.58) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL6378615 0.84 HDAC1 (0.52) L3MBTL1MAPTRXFP1HDAC3HDAC1
SCHEMBL16772764 0.83 L3MBTL1 (0.57) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL6379732 0.83 HDAC1 (0.53) L3MBTL1MAPTRXFP1HDAC3HDAC1
SCHEMBL6987866 0.83 L3MBTL1 (0.59) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL2579658 0.81 CA14 (0.53) L3MBTL1HDAC1HDAC2PPARAHDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4736848-A1 PHARMACEUTICAL COMPOSITION CONTAINING CATIONIC LIPID AND USE THEREOF Shanghai Regenelead Therapies Co., Ltd. (CN) 2026-05-06 EP disclosed
US-20250064750-A1 LIPID AND COMPOSITION USED FOR DELIVERY JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2025-02-27 US disclosed
WO-2025002352-A1 PHARMACEUTICAL COMPOSITION CONTAINING CATIONIC LIPID AND USE THEREOF 上海瑞宏迪医药有限公司 2025-01-02 WO disclosed
EP-4458806-A1 LIPID AND COMPOSITION USED FOR DELIVERY Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2024-11-06 EP disclosed
WO-2023125738-A1 LIPID AND COMPOSITION USED FOR DELIVERY 江苏恒瑞医药股份有限公司 2023-07-06 WO disclosed
WO-2023125738-A1 LIPID AND COMPOSITION USED FOR DELIVERY 江苏恒瑞医药股份有限公司 2023-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250064750-A1 LIPID AND COMPOSITION USED FOR DELIVERY H1-0, H1-2, H1-3 L3MBTL1 511/4885MAPT 644/4885RXFP1 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.